Dr Reddy's Laboratories Ltd (RDY)

30.72
0.10 0.32
NYSE : Health Care
Prev Close 30.82
Open 30.75
Day Low/High 30.67 / 30.81
52 Wk Low/High 30.22 / 50.10
Volume 31.71K
Avg Volume 337.90K
Exchange NYSE
Shares Outstanding 165.80M
Market Cap 5.13B
EPS 1.10
P/E Ratio 27.88
Div & Yield 0.31 (1.00%)

Latest News

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dr. Reddy's Laboratories Ltd. - RDY

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dr. Reddy's Laboratories Ltd. - RDY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dr.

Dr. Reddy's Q1 FY18 Financial Results

Dr. Reddy's Q1 FY18 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q1 FY18 Results On July 27, 2017

Dr. Reddy's To Release Q1 FY18 Results On July 27, 2017

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the First Quarter ended June 30, 2017 on Thursday, July 27, 2017 after the Board Meeting.

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2017 was filed with the United...

Dr. Reddy's Laboratories Limited To Present At The Jefferies 2017 Global Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6 th, 2017, in New York City.

Dr. Reddy's Q4 And FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Dr. Reddy's Laboratories Announces The Launch Of Progesterone Capsules In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium ® (Progesterone)...

Dr. Reddy's And Integra LifeSciences Enter Into An Agreement To Market And Distribute DuraGen Plus® And Suturable DuraGen® Dural Regeneration In India

Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that they have entered into an...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AG, AMZN, CBPX, CTLT, FSM, GOLD, LADR, OHI Downgrades: ESRX, GCO, NXPI, OPB, PIP, RDY, TM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Q3 And 9M FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

INVESTOR ALERT: Investigation Of Dr. Reddy's Laboratories Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Dr. Reddy's Laboratories Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether certain statements issued during 2015 by Dr.

Dr. Reddy's To Release Q3 FY17 Results On Feb 4, 2017

Dr. Reddy's To Release Q3 FY17 Results On Feb 4, 2017

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter and 9 months ended December 31, 2016 on Saturday, February 4, 2017 after the Board Meeting.

Dr. Reddy's Laboratories Announces The Launch Of Nystatin And Triamcinolone Acetonide Cream, USP In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Nystatin And Triamcinolone Acetonide Cream, USP In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Nystatin and Triamcinolone Acetonide Cream, USP, in the United States market, approved by the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CCJ, CMC, DF, DLNG, GATX, PCH, PFNX, PRAH, RDY, TMHC, VLO Downgrades: AKRX, BETR, EDGW, HLTH, KNDI, PRMW, SONC, VWR Initiations: RGNX Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Laboratories Announces The Launch Of Raloxifene HCl Tablets, USP In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Raloxifene HCl Tablets, USP In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista ® (raloxifene...

Dr. Reddy's Q2 And H1 FY17 Financial Results

Dr. Reddy's Q2 And H1 FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q2 FY17 Results On Oct 25, 2016; Earnings Call Slated For Oct 25, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q2 FY17 Results On Oct 25, 2016; Earnings Call Slated For Oct 25, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Second Quarter ended September 30, 2016 on Tuesday, October 25, 2016 after the Board Meeting.